Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases $1,354,270.50 in Stock

Posted by Jeff Wilder on May 10th, 2026

Orthofix Medical Inc. (NASDAQ:OFIX – Get Free Report) major shareholder Engine Capital Management, Lp purchased 112,950 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The stock was acquired at an average price of $11.99 per share, with a total value of $1,354,270.50. Following the completion of the purchase, the insider owned 3,783,131 shares in the company, valued at $45,359,740.69. This represents a 3.08% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

On Thursday, May 7th, Engine Capital Management, Lp purchased 30,000 shares of Orthofix Medical stock. The stock was acquired at an average price of $12.18 per share, with a total value of $365,400.00.
On Wednesday, May 6th, Engine Capital Management, Lp purchased 41,946 shares of Orthofix Medical stock. The stock was acquired at an average price of $12.23 per share, with a total value of $512,999.58.
On Wednesday, February 25th, Engine Capital Management, Lp acquired 13,061 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.96 per share, for a total transaction of $169,270.56.
On Tuesday, February 24th, Engine Capital Management, Lp acquired 124,797 shares of Orthofix Medical stock. The shares were purchased at an average cost of $12.55 per share, for a total transaction of $1,566,202.35.

Orthofix Medical Stock Performance

Shares of OFIX stock opened at $11.65 on Friday. Orthofix Medical Inc. has a one year low of $10.24 and a one year high of $16.99. The company’s 50-day moving average is $12.20 and its 200 day moving average is $13.88. The company has a market capitalization of $467.63 million, a price-to-earnings ratio of -7.72 and a beta of 0.79. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.43 and a current ratio of 2.87.

Orthofix Medical (NASDAQ:OFIX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.16. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The company had revenue of $196.71 million for the quarter, compared to the consensus estimate of $196.40 million. Sell-side analysts expect that Orthofix Medical Inc. will post -1.57 EPS for the current fiscal year.

More Orthofix Medical News

Here are the key news stories impacting Orthofix Medical this week:

Positive Sentiment: Engine Capital Management, a major shareholder, bought about 184,900 shares of Orthofix Medical across May 5-7 for roughly $2.23 million, increasing its stake to about 3.85 million shares. That kind of repeated insider accumulation often signals confidence in the company’s outlook and can support the stock. Article: Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases 30,000 Shares of Stock
Positive Sentiment: Orthofix posted first-quarter results that beat expectations, reporting a smaller-than-expected loss per share and revenue roughly in line with estimates. Investors may view the earnings beat as a sign that performance is holding up better than feared. Article: Orthofix Medical earnings report
Neutral Sentiment: Analysts maintained a consensus view of roughly Hold, but the average price target is $17.25, which is above recent trading levels and suggests some upside if execution improves. Article: Orthofix Medical Inc. (NASDAQ:OFIX) Just Reported, And Analysts Assigned A US$17.25 Price Target
Neutral Sentiment: Another report noted Engine Capital’s purchase of 30,000 shares for about $365,400, reinforcing the theme of insider confidence, though this is part of the same buying trend already reflected above. Article: Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Purchases 30,000 Shares of Stock
Negative Sentiment: Despite the earnings beat, Orthofix remains unprofitable and faces margin pressure, and the FDA’s reclassification of bone growth stimulators could increase competitive pressure in a key product category. Those issues may be limiting enthusiasm around the stock. Article: FDA reclassifies bone growth stimulators

Analysts Set New Price Targets

Several analysts recently commented on the stock. Canaccord Genuity Group cut their price objective on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Wall Street Zen downgraded shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. TD Cowen assumed coverage on shares of Orthofix Medical in a research report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price objective on the stock. Barrington Research reissued an “outperform” rating and set a $17.00 price objective on shares of Orthofix Medical in a research report on Friday, April 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.25.

Check Out Our Latest Report on OFIX

Hedge Funds Weigh In On Orthofix Medical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rubric Capital Management LP boosted its holdings in shares of Orthofix Medical by 0.7% in the second quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company’s stock worth $41,497,000 after buying an additional 26,769 shares during the last quarter. Juniper Investment Company LLC boosted its holdings in shares of Orthofix Medical by 23.3% in the fourth quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company’s stock worth $53,217,000 after buying an additional 663,278 shares during the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in shares of Orthofix Medical by 34.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after buying an additional 858,900 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of Orthofix Medical by 18.4% in the fourth quarter. Armistice Capital LLC now owns 2,648,000 shares of the medical device company’s stock worth $40,144,000 after buying an additional 412,000 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Orthofix Medical by 86.6% in the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after buying an additional 684,850 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Company Profile

(Get Free Report)

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.